Investigating the effect of mesenchymal stem cell injection on reducing complications in patients with liver cirrhosis

Studying the effect of injecting mesenchymal stem cells from deciduous tooth pulp into the portal vein under endosonography guidance in patients with liver cirrhosis to reduce disease complications

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140911019125N16

Enrollment

Registered

2026-02-24

Start date

2026-02-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reducing complications of liver failure in patients with decompensated liver cirrhosis. Congenital cirrhosis (of liver)

Interventions

Intervention group:In this single-group before-and-after clinical trial, eligible patients with liver cirrhosis will be enrolled after obtaining informed consent. Human deciduous tooth pulp-derived me

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Liver cirrhosis proven by biopsy or elastography Child-Pugh A-B and MELD=15 Age between 18 and 80 years Infertility in women Lack of specific treatment for cirrhosis Consent to participate in the study

Exclusion criteria

Exclusion criteria: Having an underlying malignancy Evidence of extrahepatic biliary diseases Presence of hepatocellular carcinoma Presence of coagulopathy and INR greater than 2 Platelets below 50,000 Active thrombosis in the hepatic and portal veins Respiratory or renal failure Active infection Transplant candidate patients Patients with severe cardiovascular disease and high blood pressure not controlled by medication Presence of severe underlying diseases Pregnant women Patient's lack of cooperation in the plan

Design outcomes

Primary

Measure	Time frame
Check liver function. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Examining the laboratory parameters of the patient related to the liver with a laboratory device.;Evaluation of the Child-pugh criterion. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients.;Evaluation of the MELD criterion. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients.	—

Measure

Time frame

Check liver function. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Examining the laboratory parameters of the patient related to the liver with a laboratory device.;Evaluation of the Child-pugh criterion. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients.;Evaluation of the MELD criterion. Timepoint: At intervals of 1, 3, 6 and 12 months after injection. Method of measurement: Completing certain questionnaires according to laboratory and clinical results of patients.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Farsinejad

Kerman University of Medical Sciences

afarsinejad@kmu.ac.ir+98 34 3132 5374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026